1 | comparative | 5,916 |
2 | confirmatory | 679 |
3 | landmark | 573 |
4 | companion | 240 |
5 | post-marketing | 232 |
6 | postmarketing | 211 |
7 | laboratory-based | 178 |
8 | trial-based | 105 |
9 | single-case | 63 |
10 | within-trial | 58 |
11 | phase-ii | 55 |
12 | duet | 52 |
13 | cross-national | 35 |
14 | morbidity-mortality | 28 |
15 | phase-2 | 27 |
16 | g551d | 25 |
17 | postmarket | 23 |
18 | clinical-trial | 22 |
19 | cohort-based | 17 |
20 | ascus-lsil | 16 |
21 | pre-experimental | 15 |
22 | post-market | 14 |
23 | drug-class | 9 |
24 | multi-trial | 8 |
25 | piggyback | 8 |
26 | split-sample | 8 |
27 | postlicensure | 7 |
28 | array-comparative | 6 |
29 | lbc+hpv | 6 |
30 | prospective-retrospective | 6 |
31 | dose-comparative | 5 |
32 | livalo | 5 |
33 | low-priority | 5 |
34 | 'diagnostic | 4 |
35 | br9601 | 4 |
36 | chemo-n0 | 4 |
37 | connectivity-based | 4 |
38 | intravenous-only | 4 |
39 | lotrel | 4 |
40 | 'comparative | 3 |
41 | clinician-level | 3 |
42 | concentration-and | 3 |
43 | medium/long-term | 3 |
44 | retts-p | 3 |
45 | 10-lb | 2 |
46 | assets-based | 2 |
47 | cinical | 2 |
48 | colon-cleansing | 2 |
49 | efficacy/ | 2 |
50 | globe/015 | 2 |
51 | h-insensitive | 2 |
52 | neuro-linguistic | 2 |
53 | neurolinguistic | 2 |
54 | neurothera | 2 |
55 | placebo-comparison | 2 |
56 | post-licensing | 2 |
57 | postmarking | 2 |
58 | prague-2 | 2 |
59 | pseudonodular | 2 |
60 | radc | 2 |
61 | realworld | 2 |
62 | response.this | 2 |
63 | short-tem | 2 |
64 | undemonstrated | 2 |
65 | 2156-bp | 1 |
66 | 60-bp | 1 |
67 | age..main | 1 |
68 | aggression-laden | 1 |
69 | analyses.one | 1 |
70 | anti-wrinkles | 1 |
71 | assignment-option | 1 |
72 | attending-level | 1 |
73 | biomarker-enriched | 1 |
74 | caffeine-enhanced | 1 |
75 | calendar-reported | 1 |
76 | certification-standard | 1 |
77 | clinical/syndromic | 1 |
78 | complementary-medicines | 1 |
79 | corresponding/comparable | 1 |
80 | cross-sectorial | 1 |
81 | deformity.two | 1 |
82 | e-partner | 1 |
83 | ee.contraceptive | 1 |
84 | enjoin | 1 |
85 | entitlement-abusive | 1 |
86 | ethnophysiological | 1 |
87 | evidence.many | 1 |
88 | follow-up.two | 1 |
89 | hpv-papanicolaou | 1 |
90 | hypnoinductive | 1 |
91 | identity-neutral | 1 |
92 | in-view | 1 |
93 | intercourse.regarding | 1 |
94 | life/cost | 1 |
95 | nosocomial-infection | 1 |
96 | nurse-only | 1 |
97 | outer-half | 1 |
98 | p16/ki-67-based | 1 |
99 | parent-targeted | 1 |
100 | patient-tumor-derived | 1 |
101 | poorly-healed | 1 |
102 | post-commercialization | 1 |
103 | prediction-guided | 1 |
104 | profile.this | 1 |
105 | pull-down/lc-ms/ms | 1 |
106 | restoration.one | 1 |
107 | risk-projection | 1 |
108 | stimulation-generated | 1 |
109 | stress-rate | 1 |
110 | study-risk | 1 |
111 | subfield-guided | 1 |
112 | swiss-noso | 1 |
113 | tbdms-protected | 1 |
114 | temporally-distinct | 1 |
115 | two-list | 1 |
116 | unpublshed | 1 |
117 | vulnerability-stress-model | 1 |
118 | whole-head-type | 1 |
119 | workplaces.the | 1 |
120 | κ. | 1 |
121 | ∼140-185 | 1 |
1 | 'comparative | 3 |
2 | 'diagnostic | 4 |
3 | 10-lb | 2 |
4 | 2156-bp | 1 |
5 | 60-bp | 1 |
6 | age..main | 1 |
7 | aggression-laden | 1 |
8 | analyses.one | 1 |
9 | anti-wrinkles | 1 |
10 | array-comparative | 6 |
11 | ascus-lsil | 16 |
12 | assets-based | 2 |
13 | assignment-option | 1 |
14 | attending-level | 1 |
15 | biomarker-enriched | 1 |
16 | br9601 | 4 |
17 | caffeine-enhanced | 1 |
18 | calendar-reported | 1 |
19 | certification-standard | 1 |
20 | chemo-n0 | 4 |
21 | cinical | 2 |
22 | clinical-trial | 22 |
23 | clinical/syndromic | 1 |
24 | clinician-level | 3 |
25 | cohort-based | 17 |
26 | colon-cleansing | 2 |
27 | companion | 240 |
28 | comparative | 5,916 |
29 | complementary-medicines | 1 |
30 | concentration-and | 3 |
31 | confirmatory | 679 |
32 | connectivity-based | 4 |
33 | corresponding/comparable | 1 |
34 | cross-national | 35 |
35 | cross-sectorial | 1 |
36 | deformity.two | 1 |
37 | dose-comparative | 5 |
38 | drug-class | 9 |
39 | duet | 52 |
40 | e-partner | 1 |
41 | ee.contraceptive | 1 |
42 | efficacy/ | 2 |
43 | enjoin | 1 |
44 | entitlement-abusive | 1 |
45 | ethnophysiological | 1 |
46 | evidence.many | 1 |
47 | follow-up.two | 1 |
48 | g551d | 25 |
49 | globe/015 | 2 |
50 | h-insensitive | 2 |
51 | hpv-papanicolaou | 1 |
52 | hypnoinductive | 1 |
53 | identity-neutral | 1 |
54 | in-view | 1 |
55 | intercourse.regarding | 1 |
56 | intravenous-only | 4 |
57 | laboratory-based | 178 |
58 | landmark | 573 |
59 | lbc+hpv | 6 |
60 | life/cost | 1 |
61 | livalo | 5 |
62 | lotrel | 4 |
63 | low-priority | 5 |
64 | medium/long-term | 3 |
65 | morbidity-mortality | 28 |
66 | multi-trial | 8 |
67 | neuro-linguistic | 2 |
68 | neurolinguistic | 2 |
69 | neurothera | 2 |
70 | nosocomial-infection | 1 |
71 | nurse-only | 1 |
72 | outer-half | 1 |
73 | p16/ki-67-based | 1 |
74 | parent-targeted | 1 |
75 | patient-tumor-derived | 1 |
76 | phase-2 | 27 |
77 | phase-ii | 55 |
78 | piggyback | 8 |
79 | placebo-comparison | 2 |
80 | poorly-healed | 1 |
81 | post-commercialization | 1 |
82 | post-licensing | 2 |
83 | post-market | 14 |
84 | post-marketing | 232 |
85 | postlicensure | 7 |
86 | postmarket | 23 |
87 | postmarketing | 211 |
88 | postmarking | 2 |
89 | prague-2 | 2 |
90 | pre-experimental | 15 |
91 | prediction-guided | 1 |
92 | profile.this | 1 |
93 | prospective-retrospective | 6 |
94 | pseudonodular | 2 |
95 | pull-down/lc-ms/ms | 1 |
96 | radc | 2 |
97 | realworld | 2 |
98 | response.this | 2 |
99 | restoration.one | 1 |
100 | retts-p | 3 |
101 | risk-projection | 1 |
102 | short-tem | 2 |
103 | single-case | 63 |
104 | split-sample | 8 |
105 | stimulation-generated | 1 |
106 | stress-rate | 1 |
107 | study-risk | 1 |
108 | subfield-guided | 1 |
109 | swiss-noso | 1 |
110 | tbdms-protected | 1 |
111 | temporally-distinct | 1 |
112 | trial-based | 105 |
113 | two-list | 1 |
114 | undemonstrated | 2 |
115 | unpublshed | 1 |
116 | vulnerability-stress-model | 1 |
117 | whole-head-type | 1 |
118 | within-trial | 58 |
119 | workplaces.the | 1 |
120 | κ. | 1 |
121 | ∼140-185 | 1 |
1 | κ. | 1 |
2 | efficacy/ | 2 |
3 | chemo-n0 | 4 |
4 | br9601 | 4 |
5 | phase-2 | 27 |
6 | prague-2 | 2 |
7 | globe/015 | 2 |
8 | ∼140-185 | 1 |
9 | neurothera | 2 |
10 | 10-lb | 2 |
11 | radc | 2 |
12 | clinical/syndromic | 1 |
13 | neuro-linguistic | 2 |
14 | neurolinguistic | 2 |
15 | 'diagnostic | 4 |
16 | g551d | 25 |
17 | caffeine-enhanced | 1 |
18 | subfield-guided | 1 |
19 | prediction-guided | 1 |
20 | biomarker-enriched | 1 |
21 | unpublshed | 1 |
22 | poorly-healed | 1 |
23 | p16/ki-67-based | 1 |
24 | trial-based | 105 |
25 | assets-based | 2 |
26 | cohort-based | 17 |
27 | laboratory-based | 178 |
28 | connectivity-based | 4 |
29 | stimulation-generated | 1 |
30 | undemonstrated | 2 |
31 | tbdms-protected | 1 |
32 | parent-targeted | 1 |
33 | calendar-reported | 1 |
34 | patient-tumor-derived | 1 |
35 | realworld | 2 |
36 | concentration-and | 3 |
37 | certification-standard | 1 |
38 | workplaces.the | 1 |
39 | corresponding/comparable | 1 |
40 | split-sample | 8 |
41 | restoration.one | 1 |
42 | analyses.one | 1 |
43 | whole-head-type | 1 |
44 | postlicensure | 7 |
45 | single-case | 63 |
46 | stress-rate | 1 |
47 | entitlement-abusive | 1 |
48 | comparative | 5,916 |
49 | 'comparative | 3 |
50 | dose-comparative | 5 |
51 | array-comparative | 6 |
52 | prospective-retrospective | 6 |
53 | hypnoinductive | 1 |
54 | h-insensitive | 2 |
55 | ee.contraceptive | 1 |
56 | outer-half | 1 |
57 | intercourse.regarding | 1 |
58 | postmarking | 2 |
59 | colon-cleansing | 2 |
60 | post-licensing | 2 |
61 | post-marketing | 232 |
62 | postmarketing | 211 |
63 | phase-ii | 55 |
64 | piggyback | 8 |
65 | landmark | 573 |
66 | study-risk | 1 |
67 | ethnophysiological | 1 |
68 | cinical | 2 |
69 | cross-sectorial | 1 |
70 | multi-trial | 8 |
71 | clinical-trial | 22 |
72 | within-trial | 58 |
73 | cross-national | 35 |
74 | identity-neutral | 1 |
75 | pre-experimental | 15 |
76 | vulnerability-stress-model | 1 |
77 | lotrel | 4 |
78 | attending-level | 1 |
79 | clinician-level | 3 |
80 | ascus-lsil | 16 |
81 | short-tem | 2 |
82 | medium/long-term | 3 |
83 | aggression-laden | 1 |
84 | age..main | 1 |
85 | enjoin | 1 |
86 | companion | 240 |
87 | post-commercialization | 1 |
88 | nosocomial-infection | 1 |
89 | risk-projection | 1 |
90 | assignment-option | 1 |
91 | placebo-comparison | 2 |
92 | livalo | 5 |
93 | swiss-noso | 1 |
94 | follow-up.two | 1 |
95 | deformity.two | 1 |
96 | retts-p | 3 |
97 | 60-bp | 1 |
98 | 2156-bp | 1 |
99 | pseudonodular | 2 |
100 | e-partner | 1 |
101 | anti-wrinkles | 1 |
102 | complementary-medicines | 1 |
103 | profile.this | 1 |
104 | response.this | 2 |
105 | pull-down/lc-ms/ms | 1 |
106 | drug-class | 9 |
107 | temporally-distinct | 1 |
108 | post-market | 14 |
109 | postmarket | 23 |
110 | duet | 52 |
111 | two-list | 1 |
112 | life/cost | 1 |
113 | hpv-papanicolaou | 1 |
114 | lbc+hpv | 6 |
115 | in-view | 1 |
116 | nurse-only | 1 |
117 | intravenous-only | 4 |
118 | evidence.many | 1 |
119 | confirmatory | 679 |
120 | morbidity-mortality | 28 |
121 | low-priority | 5 |